Jill Bargonetti

Dr. Jill Bargonetti

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Cell
Verified
Journal Article
Closed access
GBGareth L. Bond
Gareth L. Bond
WHWenwei Hu
Wenwei Hu
EBElisabeth E. Bond
Elisabeth E. Bond
HRHarlan Robins
Harlan Robins
SLStuart G. Lutzker
Stuart G. Lutzker
ALArnold J. Levine
Arnold J. Levine

1 January 2012 in Cell
Verified
Journal Article
Closed access
WFWilliam A. Freed-Pastor
William A. Freed-Pastor
HMHideaki Mizuno
Hideaki Mizuno
XZXi Zhao
Xi Zhao
ALAnita Langerød
Anita Langerød
SMSung-Hwan Moon
Sung-Hwan Moon
CPCarol Prives
Carol Prives

1 July 1992 in Nature
Verified
Journal Article
Closed access
GFGeorge Farmer
George Farmer
JBJill Bargonetti
Jill Bargonetti
HZHua Zhu
Hua Zhu
PFPaula Friedman
Paula Friedman
RPRon Prywes
Ron Prywes
CPCarol Prives
Carol Prives

1 June 1991 in Cell
Verified
Journal Article
Open access
JBJill Bargonetti
Jill Bargonetti
PFPaula N. Friedman
Paula N. Friedman
SKScott E. Kern
Scott E. Kern
BVBert Vogelstein
Bert Vogelstein
CPCarol Prives
Carol Prives
The DNA from a wide variety of human tumors has sustained mutations within the conserved p53 coding regions. We have purified wild-type and tumor-derived mutant p53 proteins expressed from baculovirus vectors and examined their interactions with SV40 DNA. Using DNAase I footprinting assays, we observed that both human and murine wild-type p53 proteins bind specifically to sequences adjacent to the late border of the viral replication origin. By contrast, mutant p53 proteins failed to bind specifically to these sequences. SV40 T antigen prevented wild-type p53 from interacting with this region. These data show that normal but not oncogenic forms of p53 are capable of sequence-specific interactions with viral DNA. Furthermore, they provide insights into the mechanisms by which viral proteins might regulate the control of viral growth and cell division.

1 January 2002 in Current Opinion in Oncology
Verified
Journal Article
Closed access
JBJill Bargonetti
Jill Bargonetti
JMJames J. Manfredi
James J. Manfredi
The tumor suppressor p53 controls numerous downstream targets that can result in variable outcomes, including apoptosis, transient growth arrest, and sustained growth arrest or senescence. The activation of p53, followed by its ability to play multiple roles in the control of genomic integrity or the elimination of damaged or tumorigenic cells, is performed by a complex process of cross-talk orchestrated to occur in the different compartments of the cell. Controlling performance of the many roles of p53 is a goal of many research groups and the focus of this review.

1 July 1992 in Genes & Development
Verified
Journal Article
Open access
PDF file
GZG P Zambetti
G P Zambetti
JBJill Bargonetti
Jill Bargonetti
KWK Walker
K Walker
CPC Prives
C Prives
ALA J Levine
A J Levine
It has been reported recently that the wild-type p53 gene product can positively regulate the expression of a test gene adjacent to the enhancer-promoter elements of the murine muscle-specific creatine kinase (MCK) gene. This discussion reports the identification of a wild-type p53 protein-specific DNA-binding element located within the p53-responsive region of the MCK enhancer-promoter element. This p53 protein/DNA-binding element has been defined by DNase I footprint analysis, which identified a 50-bp region. This 50-bp sequence was sufficient to confer wild-type p53 responsiveness on a heterologous minimal promoter. The mutant forms of p53 protein are much less capable of stimulating this DNA element. This study has identified the first example of a naturally occurring wild-type p53-specific DNA-binding element that is able to mediate positive regulation of a test gene. The results suggest a biological function in gene regulation for the wild-type p53 protein that is lost or altered in the mutant p53 proteins.